ALT 00
Alternative Names: ALT-00Latest Information Update: 20 Jan 2023
At a glance
- Originator Alterras Therapeutics
- Class Anti-inflammatories; Antifibrotics; Small molecules; Vasodilators
- Mechanism of Action Aminopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute lung injury
Most Recent Events
- 16 Dec 2022 ALT 00 is available for licensing as of 06 Jan 2023. http://www.alterras-therapeutics.com/ (Alterras Therapeutics GmbH website, January 2023)
- 15 Nov 2021 Preclinical trials in Acute lung injury (Combination therapy) in Austria (Parenteral)
- 15 Nov 2021 Pharmacodynamics data from a preclinical studies in Acute lung injury released by Alterras Therapeutics